OC 1012
Latest Information Update: 11 Oct 2006
At a glance
- Originator OraPharma
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Stomatitis
Most Recent Events
- 18 Feb 2003 OraPharma has been acquired by Johnson & Johnson
- 11 Sep 2001 Phase-I clinical trials for Stomatitis in USA (Unknown route)